Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Alebund Pharmaceuticals

Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 08, 2026

Sentiment
80
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 80
Regulatory
Alebund Pharmaceuticals announced that the U.S. United States — Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease for the treatment of IgA nephropathy…
Impact: Alebund is the developer of AP308 and the primary beneficiary of the FDA IND clearance, which advances its pipeline and positively impacts its stock.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Alebund Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.